Targeting MCs to improve therapeutic strategies was also suggested in a pre-clinical model of melanoma, where Kaesler and colleagues identified MCs accumulating in and around melanomas after anti-CTLA-4 treatment and showed that effective melanoma immune control was dependent on LPS-activated MCs that secreted CXCL10, which promoted the recruitment of effector T cells. This evidence concerns the gene CXCL10 and melanoma.